Rafael (RFL) Competitors $1.73 +0.14 (+8.81%) (As of 05:27 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RFL vs. AMRN, INZY, LXRX, LYEL, MRSN, VSTM, HURA, DRUG, CKPT, and SCPHShould you be buying Rafael stock or one of its competitors? The main competitors of Rafael include Amarin (AMRN), Inozyme Pharma (INZY), Lexicon Pharmaceuticals (LXRX), Lyell Immunopharma (LYEL), Mersana Therapeutics (MRSN), Verastem (VSTM), TuHURA Biosciences (HURA), Bright Minds Biosciences (DRUG), Checkpoint Therapeutics (CKPT), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical preparations" industry. Rafael vs. Amarin Inozyme Pharma Lexicon Pharmaceuticals Lyell Immunopharma Mersana Therapeutics Verastem TuHURA Biosciences Bright Minds Biosciences Checkpoint Therapeutics scPharmaceuticals Amarin (NASDAQ:AMRN) and Rafael (NYSE:RFL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings. Which has more risk & volatility, AMRN or RFL? Amarin has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Rafael has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Is AMRN or RFL more profitable? Amarin has a net margin of -16.33% compared to Rafael's net margin of -5,707.03%. Amarin's return on equity of -7.22% beat Rafael's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Rafael -5,707.03%-53.71%-48.78% Do analysts rate AMRN or RFL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rafael 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, AMRN or RFL? Rafael has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$241.02M0.76-$59.11M-$0.09-4.93Rafael$697K61.24-$34.41M-$1.67-1.04 Do insiders and institutionals hold more shares of AMRN or RFL? 22.3% of Amarin shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 2.0% of Amarin shares are held by insiders. Comparatively, 10.2% of Rafael shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer AMRN or RFL? In the previous week, Amarin had 1 more articles in the media than Rafael. MarketBeat recorded 5 mentions for Amarin and 4 mentions for Rafael. Amarin's average media sentiment score of 0.70 beat Rafael's score of 0.09 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rafael 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor AMRN or RFL? Amarin received 844 more outperform votes than Rafael when rated by MarketBeat users. Likewise, 74.04% of users gave Amarin an outperform vote while only 0.00% of users gave Rafael an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84474.04% Underperform Votes29625.96% RafaelOutperform VotesNo VotesUnderperform Votes2100.00% SummaryAmarin beats Rafael on 13 of the 17 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Rafael News Delivered to You Automatically Sign up to receive the latest news and ratings for RFL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RFL vs. The Competition Export to ExcelMetricRafaelPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$42.69M$6.58B$5.16B$19.11BDividend YieldN/A2.96%4.96%3.63%P/E Ratio-1.0410.6086.4740.26Price / Sales61.24195.851,126.0520.16Price / CashN/A57.1543.2721.25Price / Book0.555.124.825.26Net Income-$34.41M$150.98M$120.07M$988.83M7 Day Performance-8.47%1.72%1.23%0.54%1 Month Performance-7.98%-5.99%16.54%-5.24%1 Year Performance-5.46%6.01%28.85%11.59% Rafael Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RFLRafael0.387 of 5 stars$1.73+8.8%N/A-13.1%$42.69M$697,000.00-1.0413Short Interest ↑Gap DownHigh Trading VolumeAMRNAmarin0.3361 of 5 stars$0.45-1.9%N/A-48.5%$185.30M$241.02M-5.01360Analyst ForecastINZYInozyme Pharma1.7447 of 5 stars$2.88-3.7%$17.00+490.3%-31.5%$185.01MN/A-1.8550LXRXLexicon Pharmaceuticals1.9318 of 5 stars$0.74+3.5%$6.00+711.0%-49.5%$182.17M$5.23M-0.99285LYELLyell Immunopharma1.6744 of 5 stars$0.62+1.4%$1.00+61.0%-66.5%$181.52M$130,000.00-0.79270Gap DownMRSNMersana Therapeutics4.1303 of 5 stars$1.46-9.1%$6.00+312.4%-35.3%$179.74M$36.85M-2.39150VSTMVerastem2.6132 of 5 stars$4.01-4.3%$12.00+199.3%-54.4%$178.47M$10M-1.2650Short Interest ↑News CoverageGap DownHURATuHURA BiosciencesN/A$4.08-8.9%$13.00+218.6%N/A$172.52MN/A0.00N/AGap DownDRUGBright Minds Biosciences3.7325 of 5 stars$38.50-0.4%$75.00+94.8%+2,688.8%$170.71MN/A-56.62N/APositive NewsGap DownCKPTCheckpoint Therapeutics3.9748 of 5 stars$3.48-7.2%$13.50+287.9%+52.4%$169.94M$47,000.00-1.8910SCPHscPharmaceuticals3.3751 of 5 stars$3.37-0.6%$15.00+345.1%-45.5%$168.64M$30.28M-1.7730 Related Companies and Tools Related Companies AMRN Alternatives INZY Alternatives LXRX Alternatives LYEL Alternatives MRSN Alternatives VSTM Alternatives HURA Alternatives DRUG Alternatives CKPT Alternatives SCPH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RFL) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rafael Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rafael With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
